Loading…
Lgenia is dedicated to discovering new medicines to treat tuberculosis, malaria and Alzheimer's disease. Addressing women's health needs is equally important to our overall goal of making affordable treatments available to all patients.
To discover and develop innovative medicines that address the world's most challenging diseases, ensuring no patient is denied access to breakthrough treatments.
A world where every person has access to life-saving medications, regardless of their economic circumstances or geographic location.
Targeting four critical areas that impact millions of lives worldwide
Developing next-generation anti-TB drugs to combat drug-resistant strains and shorten treatment duration.
Creating innovative antimalarial compounds that target resistant parasites and prevent transmission.
Pioneering neuro-immune targets to slow cognitive decline and preserve quality of life.
Advancing non-hormonal contraceptive discovery to expand reproductive health options and access.
Key milestones in our mission to discover life-saving medications
Dr. Philip A. Hipskind founded Lgenia Inc. with a vision to make breakthrough medicines accessible to all patients.
Became a collaborating organization of the TB Drug Accelerator, supported by the Bill and Melinda Gates Foundation.
Strategic partnership with Indiana University's NIH-sponsored TREAT-AD Center for Alzheimer's disease research.
Expanded partnership to include the Malaria Drug Accelerator program for antimalarial drug discovery.
Added a new discovery program focused on non-hormonal contraceptives to broaden our reproductive health portfolio.
World-class scientists dedicated to discovering life-saving medications
Chief Executive Officer & Chief Scientific Officer
Dr. Philip A. Hipskind earned his BS at Indiana University. He then went on to get his doctorate in organic chemistry at Stanford University in 1991. While earning his Ph.D. he was both a Tamaki Foundation and an American Chemical Society Fellow.
Senior Portfolio Director
Dr. Cynthia D. Jesudason earned her B.A. from Oxford University and her Ph.D. in Organic Chemistry (on the first asymmetric synthesis of the complete daphnane skeleton) with Professor Paul Wender at Stanford University in 1995. She joined Lilly Research Laboratories as a medicinal chemist that same year.
Senior Portfolio Director
Dr. David Mendel earned his B.A. in Chemistry from Carleton College and a Ph.D. at CalTech. Thereafter, as an American Cancer Society Postdoctoral Fellow, Dr. Mendel expanded the boundaries of unnatural amino acid mutagenesis in Peter Schultz's lab at the University of California, Berkeley.
Senior Portfolio Director
Karen Lobb has over 25 years of lab experience synthesizing, purifying, and analyzing organic molecules for biological structure-activity relationships (SAR).
Senior Portfolio Director
Leonard Winneroski has over 34 years of experience in small molecule drug discovery and chemical process research and development. He received his B.S. from Central Michigan University in 1988 and his M.Sc. from Butler University in 1995.
Senior Portfolio Director
Dr. Miles Siegel earned his B.A. in Chemistry from Dartmouth College in 1985. Following a two year stint as a small scale industrial chemist at Eastman Kodak, Dr. Siegel obtained his Ph.D. at the University of Chicago under the mentorship of Professor Jeffery Winkler, where he researched photochemical approaches to the total synthesis of alkaloid natural products. Upon completing his Ph.D., he performed post-doctoral research in the labs of Professor Harry Wasserman at Yale University, studying the synthetic methodology of vicinal tricarbonyl compounds.
Senior Portfolio Director
Dr. Kenn Henry earned his B.S. in chemistry from the University of Michigan in 1987. He obtained his Ph.D. in 1994 from Indiana University in the lab of Professor Paul A. Grieco — studying natural product synthesis and synthetic methodology in organic salt solutions. Dr. Henry moved to Duke University and developed synthetic routes to the natural product azadirachtin as a Postdoctoral research associate under the direction of Professor Bert Fraser-Reid.
Senior Portfolio Director
Greg Durst received his B.S. in Chemistry from Ohio Northern University and began his career at Ball Corporation Analytical Laboratories in Muncie, IN, performing analyses of metal container coatings and polymer food containers. During this time, he began his M.S. degree in Chemistry at Ball State University, completing a computational thesis that launched his long-standing focus on applying modeling to chemical and drug discovery problems.
Director of Research Operations
Elizabeth Aaron is a highly accomplished chemist with over three decades of experience spanning drug discovery, quality management, and OTC pharmaceutical manufacturing. She earned her Bachelor of Arts in Chemistry from The Ohio State University, with minors in Microbiology and Romanian Language, and launched her career at Eli Lilly and Company in Indianapolis, where she spent nearly two decades as an organic chemist in Discovery Chemistry Research. During her time at Lilly, she designed and synthesized novel compounds for drug development in the areas of cancer and neuroscience, contributing to multiple peer-reviewed publications and patents, including work on cyclin-dependent kinase inhibitors and corticotropin releasing factor receptor antagonists.
The principles that guide our research and development efforts
Pursuing the highest standards in scientific research and drug development to deliver breakthrough therapies.
Ensuring that life-saving medications are available and affordable to patients regardless of their circumstances.
Driven by empathy for patients and families affected by devastating diseases that need better treatment options.
Building partnerships with leading institutions and organizations to accelerate medical breakthroughs.